Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sean Whittaker

Showing results (51-60 of 81) with videos related to

Pageof 9
Sort By:
Blood|February 22, 2007
Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphomaYoun H Kim, Madeleine Duvic, Erik Obitz, et al.
Blood|June 24, 2008
European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomasNancy J Senff, Evert M Noordijk, Youn H Kim, et al.
The Lancet. Oncology|June 30, 2019
IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trialMartine Bagot, Pierluigi Porcu, Anne Marie-Cardine, et al.
Expert Review of Clinical Immunology|March 27, 2024
Tumor associated macrophages as key contributors and targets in current and future therapies for melanomaShabana Habib, Gabriel Osborn, Zena Willsmore, et al.
The British Journal of Dermatology|February 26, 2026
Phenotypic, functional, prognostic and predictive significance of B-cell and antibody responses in human melanoma: A scoping reviewLucy Booth, Xinyi Chen, Katie Stoker, et al.
Blood|June 2, 2007
Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)Elise Olsen, Eric Vonderheid, Nicola Pimpinelli, et al.
European Journal of Cancer (Oxford, England : 1990)|April 3, 2017
European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - Update 2017Franz Trautinger, Johanna Eder, Chalid Assaf, et al.
European Journal of Dermatology : EJD|May 5, 2017
A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-cell lymphoma - EORTC 21081 (NCT01098656): results and lessons learned for future trial designsMartine Bagot, Baktiar Hasan, Sean Whittaker, et al.
Journal of Clinical Pathology|October 5, 2006
CD56-positive haematological neoplasms of the skin: a multicentre study of the Cutaneous Lymphoma Project Group of the European Organisation for Research and Treatment of CancerChalid Assaf, Sylke Gellrich, Sean Whittaker, et al.
Journal for Immunotherapy of Cancer|May 31, 2025
Circulating immunoregulatory B cell and autoreactive antibody profiles predict lack of toxicity to anti-PD-1 checkpoint inhibitor treatment in advanced melanomaZena N Willsmore, Lucy Booth, Akshay Patel, et al.
Pageof 9

Showing results (51-60 of 81) with videos related to

Sort By:
Pageof 9
Blood|February 22, 2007
Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphomaYoun H Kim, Madeleine Duvic, Erik Obitz, et al.
Blood|June 24, 2008
European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomasNancy J Senff, Evert M Noordijk, Youn H Kim, et al.
The Lancet. Oncology|June 30, 2019
IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trialMartine Bagot, Pierluigi Porcu, Anne Marie-Cardine, et al.
Expert Review of Clinical Immunology|March 27, 2024
Tumor associated macrophages as key contributors and targets in current and future therapies for melanomaShabana Habib, Gabriel Osborn, Zena Willsmore, et al.
The British Journal of Dermatology|February 26, 2026
Phenotypic, functional, prognostic and predictive significance of B-cell and antibody responses in human melanoma: A scoping reviewLucy Booth, Xinyi Chen, Katie Stoker, et al.
Blood|June 2, 2007
Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)Elise Olsen, Eric Vonderheid, Nicola Pimpinelli, et al.
European Journal of Cancer (Oxford, England : 1990)|April 3, 2017
European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - Update 2017Franz Trautinger, Johanna Eder, Chalid Assaf, et al.
European Journal of Dermatology : EJD|May 5, 2017
A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-cell lymphoma - EORTC 21081 (NCT01098656): results and lessons learned for future trial designsMartine Bagot, Baktiar Hasan, Sean Whittaker, et al.
Journal of Clinical Pathology|October 5, 2006
CD56-positive haematological neoplasms of the skin: a multicentre study of the Cutaneous Lymphoma Project Group of the European Organisation for Research and Treatment of CancerChalid Assaf, Sylke Gellrich, Sean Whittaker, et al.
Journal for Immunotherapy of Cancer|May 31, 2025
Circulating immunoregulatory B cell and autoreactive antibody profiles predict lack of toxicity to anti-PD-1 checkpoint inhibitor treatment in advanced melanomaZena N Willsmore, Lucy Booth, Akshay Patel, et al.
Pageof 9